OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $18.67M |
| Net Income (Most Recent Fiscal Year) | $-64.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.72 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.47 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -118.86% |
| Net Margin (Trailing 12 Months) | -115.12% |
| Return on Equity (Trailing 12 Months) | -16.59% |
| Return on Assets (Trailing 12 Months) | -14.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.80 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.80 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 144.78M |
| Free Float | 130.59M |
| Market Capitalization | $642.84M |
| Average Volume (Last 20 Days) | 2.37M |
| Beta (Past 60 Months) | 0.62 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |